Climb Bio announced favorable initial Phase 1 safety data and translational modeling results for CLYM116, an anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The data, presented at the European Renal Association Congress 2026, showed CLYM116 was well tolerated in healthy volunteers with no serious adverse events, supporting further clinical development. The company plans to share more pharmacokinetic and safety data later this year and expects Mabworks to begin dosing IgAN patients in a Phase 2 study in Q3 2026. This progress highlights CLYM116's potential as a novel, less frequent dosing treatment for IgAN.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...
Allied Critical Metals announced positive assay results from its 2026 drilling campaign at the Santa Helena Breccia, part of the Borralha Tungsten Project in Portugal. The first drill hole confirmed broad zones of high-grade tungsten mineralization, ...
Ethereum's price rose about 11% over the past week to around $1,920, outperforming major cryptocurrencies like Bitcoin and Solana. This rally is fueled by $96 million inflows into U.S. spot Ether ETFs early in the week, with BlackRock's ETHA product ...
The XRP Ledger has surpassed 8 million activated accounts, marking steady growth since March 2026. However, daily active addresses have declined to a 2026 low of 25,350, indicating less frequent user engagement despite overall adoption. XRP's price f...
